《大行》花旗:中国制药及生物科技ESMO数据再获验证 看好石药、恒瑞、信达生物及科伦博泰

阿斯达克财经
Nov 02

花旗发表研究报告指,ESMO 2026标志着中国制药及生物科技又迈出了重要一步,中国原研资产于多项全球关键研究交出具说服力数据,并展现强劲的中国至全球一致性、高关注度临床结果,以及超越既有靶点的创新。该行认为,这有助降低行业风险,提升对全球监管路径、海外商业化及跨境合作可持续性的信心,并可能支持具备差异化、具国际竞争力管线的公司结构性重估。该行指出,多项备受关注读数优于投资者预期,包括...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10